Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer.

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,” said Robert I. Blum, Cytokinetics' President and Chief Executive Officer.“ ...

Robert Blum. The likelihood now is that Cytokinetics will have to re-align itself around aficamten, currently in the SEQUOIA-HCM pivotal trial which is due to generate results later in 2023 ...

Cytokinetics' chief executive, Robert Blum, said the new deal with Royalty Pharma “reinforces our shared conviction in the value of our cardiac myosin-focused pipeline of drug candidates.” ...

New England Patriots owner Robert Kraft is back. He is again addressing racism. He is again asking America to take a hard look at itself. He is again using America's biggest game as a vehicle to ...